ELAN
Elanco Animal Health Incorporated · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 128 | +5 | 426.57M | $10.50B | +12 | −8 |
| Q1 2026 | 127 | -2 | 403.59M | $9.65B | +6 | −9 |
| Q4 2025 | 128 | +1 | 433.50M | $9.81B | +4 | −2 |
| Q3 2025 | 20 | -1 | 348.71M | $7.02B | — | −2 |
| Q2 2025 | 19 | +2 | 313.01M | $4.47B | +3 | −1 |
| Q1 2025 | 14 | -2 | 167.03M | $1.75B | +1 | −3 |
| Q4 2024 | 16 | -2 | 168.00M | $2.03B | — | −2 |
| Q3 2024 | 17 | +1 | 175.40M | $2.58B | +1 | — |
| Q2 2024 | 16 | — | 207.32M | $2.99B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox ✦ | 83.58M | — | $1.21B | 0.7% | n/c | 1 | SEC ↗ |
| 2 | PRIMECAP Management ✦ | 52.80M | — | $761.94M | 0.6% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 28.07M | — | $405.02M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Citadel Advisors ✦ | 12.78M | — | $184.41M | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 9.42M | — | $135.90M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 7.80M | — | $112.63M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Norges Bank ✦ (passive) | 3.88M | — | $55.95M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 3.36M | — | $48.50M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 9 | D. E. Shaw & Co. ✦ | 2.53M | — | $36.53M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 1.40M | — | $20.15M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 1.39M | — | $19.99M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Gotham Asset Management ✦ | 160.57K | — | $2.32M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 71.23K | — | $1.03M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Two Sigma Investments ✦ | 35.83K | — | $517,056 | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 24.54K | — | $354,170 | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Arrowstreet Capital ✦ | 23.11K | — | $334,000 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 512 holders, 543.55M shares, $11.98B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 40.00K sh @ 23.40 · $935,920
Officer · GC AND CORP SEC · 4.00K sh @ 23.58 · $94,273
Director · 5.00K sh @ 21.82 · $109,100
Director · 10.00K sh @ 23.68 · $236,850
Officer · EVP and CFO · 4.20K sh @ 23.08 · $96,926
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology